Variants in CDA and ABCB1 are predictors of capecitabinerelated adverse reactions in colorectal cancer

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6422-6430

  García González, Xandra ^a   Cortejoso, Lucía ^a   García, María I ^a   García Alfonso, Pilar ^a   Robles, Luis ^b   Grávalos, Cristina ^b   González Haba, Eva ^a   Marta, Pellicer ^a   Sanjurjo, María ^a   López Fernández, Luis A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Chemotherapy; Flouropyrimidine; Genetics; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEVACIZUMAB; CAPECITABINE; CETUXIMAB; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PANITUMUMAB; ABCB1 PROTEIN, HUMAN; CYTIDINE DEAMINASE; MULTIDRUG RESISTANCE PROTEIN;

ABCB1 GENE; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER PATIENT; CDA GENE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ENOSF1 GENE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAND FOOT SYNDROME; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY DELAY; TYMS GENE; VOMITING; COLORECTAL NEOPLASMS; GENETIC VARIATION; GENETICS; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAPECITABINE; COLORECTAL NEOPLASMS; CYTIDINE DEAMINASE; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84925627248     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3289     Document Type: Article

References (37)

1. Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res 2011; 3: 79-89.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M, Wagner M, Fishel R, Boothman DA. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol 2009; 158: 679-92.
4. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006; 6: 16-21.
5. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs 2008; 19: 447-464.
6. Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci 2012; 9: 33-9.
7. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MKB, Quirke P, Seymour MT. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 2009; 27: 5519-28.
8. Strimpakosa S, Syrigos KN, Saif MW. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J 2009; 9: 147-60.
9. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94: 640-5.
10. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 2014; 74: 2545-54.
11. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32: 1031-9.
12. Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: A prospective study. Ann Oncol 2011; 22: 355-361.
13. Boige V, Mendiboure J, Pignon J-P, Loriot M-A, Castaing M, Barrois M, Malka D, Trégouët D-A, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28: 2556-2564.
14. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-3233.
15. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, De Gramont A. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010; 69: 58-66.
16. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8: 278-88.
17. Thomas F, Motsinger-Reif A, Hoskins JM, Dvorak A, Roy S, Alyasiri A, Myerson RJ, Fleshman JW, Tan BR, McLeod HL. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 2011; 105: 1654-62.
18. Kristensen MH, Pedersen PL, Melsen G V, Ellehauge J, Mejer J. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res 2010; 38: 870-83.
19. Afzal S, Gusella M, Vainer B, Vogel UB, Andersen JT, Broedbaek K, Petersen M, Jimenez-Solem E, Bertolaso L, Barile C, Padrini R, Pasini F, Jensen SA et al. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients. Clin Cancer Res 2011; 17: 3822-3829.
20. Gonzalez-Haba E, García MI, Cortejoso L, López-Lillo C, Barrueco N, García-Alfonso P, Alvarez S, Jiménez JL, Martín ML, Muñóz-Fernández M a, Sanjurjo M, López-Fernández L a. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics 2010; 11: 1715-23.
21. Cortejoso L, García MI, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L a. [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farm Hosp 2014; 38: 283-90.
22. Caronia D, Martin M, Sastre J, de la Torre J, García-Sáenz JA, Alonso MR, Moreno LT, Pita G, Díaz-Rubio E, Benítez J, González-Neira A. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. Clin Cancer Res 2011; 17: 2006-13.
23. Blagosklonny M V, Darzynkiewicz Z. Cyclotherapy: protection of normal cells and unshielding of cancer cells. Cell Cycle; 1: 375-82.
24. Blagosklonny M V. How cancer could be cured by 2015. Cell Cycle 2005; 4: 269-78.
25. Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? Clin Colorectal Cancer 2009; 8: 231-4.
26. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genomics 2012; 22: 290-304.
27. Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JHM, Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014. doi:10.1038/bjc.2014.467.
28. Van Huis-Tanja LH, Gelderblom H, Punt CJA, Guchelaar H-J. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. Pharmacogenet Genomics 2013; 23: 208-18.
29. Monteagudo C, Mariscal-Arcas M, Palacin A, Lopez M, Lorenzo ML, Olea-Serrano F. Estimation of dietary folic acid intake in three generations of females in Southern Spain. Appetite 2013; 67: 114-8.
30. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, Maisey N, Ross P, Sanderson JD, Marinaki AM. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013; 108: 2505-15.
31. Carpi FM, Vincenzetti S, Ubaldi J, Pucciarelli S, Polzonetti V, Micozzi D, Mignini F. CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population R esearch A rticle. 2013;: 769-781.
32. Abraham A, Varatharajan S, Abbas S, Zhang W, Shaji R V, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, Balasubramanian P. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 2012; 13: 269-82.
33. Jennings BA, Loke YK, Skinner J, Keane M, Chu GS, Turner R, Epurescu D, Barrett A, Willis G. Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One 2013; 8: e78053.
34. Cortejoso L, López-Fernández L a. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics 2012; 13: 1173-91.
35. Nieto Montesinos R, Béduneau A, Pellequer Y, Lamprecht A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release 2012; 161: 50-61.
36. Chockalingam S, Ghosh SS. Amelioration of cancer stem cells in macrophage colony stimulating factor-expressing U87MG-human glioblastoma upon 5-fluorouracil therapy. PLoS One 2013; 8: e83877.
37. Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-14.